Cytori Announces Proposed Public Offering of Common Stock

Cytori Announces Proposed Public Offering of Common Stock

SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. ( Cytori or the Company ) (NASDAQ:

CYTX) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Cytori also expects to grant to the underwriter for the offering a 45-day option to

purchase an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Cytori. Cytori currently intends to use the net proceeds of the offering for working capital and

general corporate purposes, including funding of the HABEO and ATI-0918 development programs.

Maxim Group LLC is acting as sole book-running manager for the offering. The offering is subject to market conditions, and there can be no

assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

described above are being offered by Cytori pursuant to a registration statement (File No. 333-195846) previously filed and declared effective by the Securities and Exchange Commission (SEC). A

preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these

securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the preliminary

prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at

212-895-3745. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms

for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori

Cell Therapy may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori s

proprietary technologies and products. Cytori Nanomedicine is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.

Safe Harbor Statement

Cytori cautions you that statements included in this press release that are not a description of historical facts are forward-looking

statements. Words such as expect, anticipate, intend, plan, believe, seek, estimate, think, may, could, will,

would, should, continue, potential, likely, opportunity and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the

exclusive means of identifying forward-looking statements. These statements are based on Cytori s current beliefs and expectations. These forward-looking statements include statements regarding Cytori s expectations on the completion and

timing of the offering and the anticipated use of proceeds therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Cytori that any of its plans will be achieved. Actual results may differ from those set

forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties inherent in Cytori s

business, including those described in Cytori s periodic

filings with the SEC and the prospectus supplement and related prospectus for this offering filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements,

which speak only as of the date hereof. There may be events in the future that Cytori is unable to predict, or over which it has no control, and Cytori s business, financial condition, results of operations and prospects may change in the

future. Cytori assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made, except as required by applicable law. All forward-looking statements are qualified

in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Cytori Therapeutics, Inc.

Tiago Gir o, +1 (858) 458.0900

Source: Cytori Therapeutics